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Objective: Pain in knee osteoarthritis (OA) has historically been attributed to peripheral pathophysiology;
however, the poor correspondence between objective measures of disease severity and clinical symp-
toms suggests that non-local factors, such as altered central processing of painful stimuli, also contribute
to clinical pain in knee OA. Consistent with this notion, recent evidence demonstrates that patients with
knee OA exhibit increased sensitivity to painful stimuli at body sites unaffected by clinical pain.
Design: In order to further investigate the contribution of altered pain processing to knee OA pain, the
current study tested the hypothesis that symptomatic knee OA is associated with enhanced sensitivity to
experimental pain stimuli at the knee and at remote body sites unaffected by clinical pain. We further
anticipated that pain sensitivity would differ as a function of the OA symptom severity. Older adults with
and without symptomatic knee OA completed a series of experimental pain assessments. A median split
of the Western Ontario and McMaster Universities Index of Osteoarthritis (WOMAC) was used to stratify
participants into low vs high OA symptom severity.
Results: Compared to controls and the low symptom group, individuals in the high symptom group were
more sensitive to suprathreshold heat stimuli, blunt pressure, punctuate mechanical, and cold stimuli.
Individuals in the low symptomatic OA group subgroup exhibited experimental pain responses similar to
the pain-free group on most measures. No group differences in endogenous pain inhibition emerged.
Conclusions: These ﬁndings suggest that altered central processing of pain is particularly characteristic of
individuals with moderate to severe symptomatic knee OA.
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r Ltd on behalf of Osteoarthritis ReIntroduction
Knee osteoarthritis (OA) is one of the most common causes of
physical impairment and pain in the United States1e3. While
objective structural changes in the joint characterize radiographic
OA4, subjective symptoms such as pain and physical functioning
often are not strongly associated with measures of primary damage
to knee tissues. For example, radiographic OA can be observed in
individuals without pain (i.e., asymptomatic) and severity of
radiographic OA is not highly associated with OA-related pain and
disability4e7. While radiographic changes are important in knee OA,
it is evident that other biological and psychological factors
contribute to OA-related pain.search Society International.
C.D. King et al. / Osteoarthritis and Cartilage 21 (2013) 1243e12521244One factor that may contribute to symptomatic OA is individual
differences in transmission and modulation of nociceptive infor-
mation by the peripheral and central nervous system. OA has been
historically considered a peripheral disease (i.e., nociceptive dam-
age at the knee8); however, central mechanisms thatmodulate pain
contribute importantly to OA symptomatology9. The inﬂuence of
these central mechanisms can be observed by assessing perceptual
responses to quantiﬁable noxious stimuli at the knee (local
hyperalgesia) and in areas remote to the knee (generalized hyper-
algesia). Recent studies have highlighted the clinical relevance of
altered central pain processing in OA, ﬁnding that individuals
reporting more severe clinical pain in the past twenty-four10 or
forty-eight11 hours showed greater sensitivity to experimental
stimulation.
The current study investigated whether altered central pain
processing was associated with the presence and symptomatic
severity of knee OA. We sought to extend the ﬁndings of previous
studies10,11 by including a larger and more diverse community-
based sample and a more comprehensive assessment of clinical
symptoms. Thus, we conducted a comprehensive battery of
experimental pain procedures, including a measure of conditioned
pain modulation (CPM), in a large cohort of middle-aged and older
adults with and without symptomatic knee OA. Individuals with
symptomatic OA were classiﬁed as high vs low symptom severity
based on responses to the Western Ontario and McMaster Uni-
versities Index of Osteoarthritis (WOMAC), a standardized ques-
tionnaire measure of knee symptoms. We hypothesized that
greater experimental pain sensitivity would be observed in in-
dividuals with more severe OA symptoms relative to those with
lower OA symptom severity. The latter group also would exhibit
greater sensitivity than persons without knee pain.
Methods
Participants
A community-based sample (n ¼ 316) was recruited for an
ongoing project at the University of Florida (UF) and the University
of Alabama at Birmingham (UAB) between January 2010 and
August 2012. The major aim of the project was to elucidate racial/
ethnic differences in pain and limitations among individuals with
osteoarthritic disease (Understanding Pain and Limitations in
Osteoarthritic Disease). All procedures were reviewed and
approved by the UF and UAB Institutional Review Boards.
Inclusion criteria
All participants were between the ages of 45 and 85 years of age
and self identiﬁed as either African American (AA) or non-Hispanic
whites (NHW). For the OA group (n ¼ 209), participants presented
with unilateral or bilateral symptomatic knee OA based upon
American College of Rheumatology clinical criteria12 including self-
reported unilateral or bilateral knee pain. Controls (n ¼ 107) re-
ported no knee pain, though they could have pain unrelated to
arthritis at other body sites. Additional exclusion criteria (see
Supplementary materials) were used during the screening process
to eliminate the inﬂuence of confounding variables such as un-
controlled hypertension (>150/95), peripheral neuropathy, or daily
opioid use.
Study overview
Participants attended two separate visits for a health assess-
ment session (i.e., general health and demographic information)
and a quantitative sensory testing session (see Supplementary
Materials, Supplementary Table I).Experimental pain tests
The current study included four commonly used sensory testing
procedures: heat, mechanical, cold, and CPM. Using the American
College of Rheumatology clinical criteria12 for symptomatic knee
OA, the participants’ most symptomatic/painful knee was desig-
nated as the index knee for future research considerations
including the testing site. Thermal pain sensitivity was probed with
several methods to detect the ﬁrst sensations of warmth (i.e.,
warmth threshold (WTh)) and pain (i.e., heat pain
threshold (HPTh)), pain tolerance (i.e., heat pain tolerance (HPTo)),
and temporal summation of heat pain. Testing sites included the
medial portion of the index knee (medial joint line, patella, and
tibial tuberosity distal to the joint) and the ipsilateral forearm
(between the ventral wrist and below the antecubital space). For all
of the thermal procedures, contact heat stimuli were delivered
using a computer-controlled Medoc Pathway (Pain & Sensory
Evaluation System, Ramat Yishai, Israel). The position of the ther-
mode was moved between trials to avoid sensitization or habitu-
ation of cutaneous receptors. Mechanical pain sensitivity was
probed with two methods: pressure pain and cutaneous mechan-
ical stimulation. Pressure pain testing was performed on the index
knee and several non-knee sites ipsilateral to the index knee, and
cutaneous mechanical testing was conducted on the index knee
and ipsilateral hand. The order of testing was counterbalanced
between the two procedures. Following the thermal and mechan-
ical procedures, cold sensitivity was assessed with a modiﬁed cold
pressor test (CPT). The procedure consisted of three one-minute
hand immersions in a cold-water bath (Thermo Scientiﬁc Refrig-
erated Bath), which was set at 16, 12, and 8 C. The last sensory test
included a measure CPM, a marker of endogenous pain inhibition.
CPM was evaluated by determining the ability of a cold-water
immersion (right hand immersion) for 1 min to diminish ratings
of heat pain at the left forearm, as performed for the temporal
summation of heat pain test.
Self-reported clinical assessments
Knee pain and function
After enrollment into the study, knee pain and function were
assessed with several validated measures including the Graded
Chronic Pain Scale (GCPS), which measures the severity of knee
pain (i.e., current, worst, and average intensity) and disability over
the past 6 months13, and the 4-point scale version of the WOMAC
(score range: 0e96), which is a commonly used instrument for
assessing pain, stiffness, and physical limitations related to knee OA
in the past 48 h14,15. To stratify individuals with symptomatic OA
into low (n ¼ 113, WOMAC score <33) and high (n ¼ 96, WOMAC
score 34) symptom severity, a median split of the total WOMAC
score was used.
Widespread pain (WPS)
WPS was determined16 by determining presence of pain in four
body quadrants (i.e., pain in right and left lower body and the right
and left upper body) and the presence of axial skeletal pain (see
Supplementary materials for more details).
Data analysis
Data analysis was performed using SPSS (v20, IBM). Group dif-
ferences on continuous variables were adjusted for standard
covariates (i.e., Race, Study Site, Age, and Gender), and assessed
using analysis of covariance (ANCOVA). Additional covariates were
used in a subset of analyses including testing site, temperature, and
sequence. For cutaneous mechanical stimuli, the pain intensity
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(i.e., tenth trial) was assessed using repeated measure analysis of
covariance (RM-ANOVA) with a GreenhouseeGeisser correction as
appropriate. Pair-wise comparisons among the different groups
were conducted with Bonferroni corrections. 95% conﬁdence in-
tervals (lower limit, upper limit) are reported with adjusted means.
Partial eta squared (hp2) are presented as measures of effect size
(hp2 ¼ .01 is considered a small effect, hp2 ¼ .06 a medium-sized
effect and partial hp2 ¼ .14 a large effect17).
Results
Demographic characteristics
The demographic characteristics of the sample are presented in
Table I. No group differences emerged in age, gender or marital
status (P’s > .05). The high symptom severity OA group, compared
to the other two groups, had a higher proportion of AAs, a higher
body mass index (BMI), and reported less education compared to
the other two groups.
Clinical pain and disability
As expected, after controlling for covariates, the high symptom
severity OA group reported greater pain severity, stiffness, and
disability related to knee OA in the past 48 h on the WOMAC and
greater pain severity and disability over the past 6 months on the
GCPS, compared to the other two groups (Table I). In addition,
participants in the low symptomatic knee OA group reported more
pain and disability than the pain-free control group (P < .001) onTable I
Adjusted means (95% conﬁdence interval) for demographic and clinical pain characterist
Controls (N ¼ 107) Sym
Low
Demographic characteristics
Age (years)x 56.8 (55.3, 58.4) 58.1
BMI (weight/height2)x 28.7 (27.2, 30.2)* 29.3
Education (%  HH) 71.9% 66.4
Employment (% NoW) 50.5% 40.7
Gender (%F) 65.4% 72.6
Marital status (% married) 44.7% 45.1
Race (%NHW) 77.6% 59.3
WPS
% Subjects with WPS .9% 15.0
Number of sites e total group .98 (.4, 1.6) 3.58
Clinical outcomes
WOMAC
Total score (range 0e96)x 3.5 (1.5, 5.4)*,z 18.4
Subscales
Pain (range 0e20)x .7 (.2, 1.2)*,z 4.2 (
Stiffness (range 0e8)x .5 (.2, .7)*,z 2.1 (
Physical function (range 0e68)x 2.3 (.8, 3.7)*,z 12.1
GCPS
Characteristic pain intensity (range 0e100)x 13.4 (9.8, 16.9)*,z 37.4
Disability score (range 0e100)x 4.9 (1.4, 8.6)*,z 24.9
Grading chronic pain grade
0 e Normal 59 3
I e Low pain intensity 42 75
II e High pain intensity 5 24
III e Moderate disability 0 6
IV e High disability 0 3
Knee pain duration
Pain on most days (months)x .17 (10.5, 19.5)* 24.7
Abbreviations: High School (HH); Not working (NoW); Yes in past year (Y); Knee Injury
* Group comparisons: Signiﬁcant group difference between the control and high sym
y Group comparisons: Signiﬁcant group difference compared between the low and hi
z Group comparisons: Signiﬁcant group difference compared between the control and
x Covariates for adjusted analysis: Controlling for race (0 ¼ NHW, 1 ¼ AA), age, WPS (0
covariates.these measures. Finally, differences were observed for the presence
of WPS, the number of body sites with pain, and months with pain
experienced on most days (P’s < .001) in which participants in the
high symptomatic knee OA group were more likely to have WPS,
reported a greater number of sites with pain, and experienced knee
pain for a longer period of time compared to the other groups
(P’s < .01).
Heat pain
Table II shows the mean temperature and pain intensity ratings
for WTh, HPTh, and HPTo in control and symptomatic knee OA
groups. No differences were observed for WTh at the forearm and
the knee (P’s > .05) after controlling for covariates. However, the
high symptomatic OA group reported greater pain at HPTh and
HPTo at the forearm compared to the control and low symptomatic
OA group (P’s < .05), after controlling for the temperature at HPTh
and HPTo. Similar differences were observed at the knee for HPTh
but not HPTo.
Table III displays the responses of all groups to repeated
suprathreshold heat stimuli (i.e., temporal summation) at the
forearm and knee. After controlling for covariates, group differ-
ences in the pain ratings at the ﬁrst trial were observed at 44, 46,
and 48 C at the forearm and knee (P’s < .02). Based on pair-wise
comparisons, participants in the control and low symptomatic
knee OA groups reported less pain than participants in the high
symptomatic knee OA group at 46 and 48 C (P’s < .01) at each site.
No differences were observed between control and low symp-
tomatic knee OA groups. Table III also shows that no group differ-
ences in temporal summation (i.e., change scores from ﬁrst ratingics of healthy controls and individuals with low and high symptomatic knee OA
ptomatic knee OA Analysis (bold if signiﬁcant)
(N ¼ 113) High (N ¼ 96)
(56.7, 59.5) 56.4 (54.8, 58.1) F ¼ 1.42, n.s., hp2 ¼ .01
(27.9, 30.6)y 33.5 (31.9, 35.1) F[ 9.49, P < .001, hp2 [ .06
% 45.8% c2[ 16.08, P < .001
% 60.4% c2[ 8.08, P < .05
% 66.7% c2 ¼ 1.48, n.s.
% 35.4% c2 ¼ 2.52, n.s.
% 34.4% c2[ 38.87, P < .001
% 36.5% c2[ 46.1, P < .001
(2.9, 4.2) 7.4 (6.6, 8.1) F[ 9.49, P < .001, hp2 [ .06
(16.7, 20.2)y 49.6 (47.5. 51.7) F[ 450, P < .001, hp2 [ .75
3.8, 4.7)y 10.3 (9.7, 10.8) F[ 310.01, P < .001, hp2 [ .67
1.9, 2.3)y 4.6 (4.3, 4.9) F[ 184.2, P < .001, hp2 [ .55
(10.8, 13.4)y 34.8 (33.2, 36.4) F[ 392.91, P < .001, hp2 [ .72
(34.1, 40.6)y 59.4 (55.5, 63.2) F[ 130.21, P < .001, hp2 [ .46
3 (21.5, 28.3)y 57.2 (53.1, 61.2) F[ 151.47, P < .001, hp2 [ .51
c2[ 252.63, P < .001
0
13
25
29
27
(11.8, 37.5)y 57.8 (43.7, 71.8) F[ 11.66, P < .001, hp2 [ .10
Osteoarthritis Outcome Score Physical Function (KOOS-PS).
ptomatic knee OA groups (P < .01, Bonferroni).
gh symptomatic knee OA groups (P < .01, Bonferroni).
low symptomatic knee OA groups (P < .01, Bonferroni).
¼ No, 1 ¼ Yes), gender (0 ¼ Female, 1 ¼Male), and study site (0 ¼ UF, 1 ¼ UAB) as a
Table II
Adjusted means (95% conﬁdence interval) for warmth and HPThs, HPTo, and heat pain ratings at the forearm and knee in healthy controls and individuals with low and high
symptomatic knee OA (95% CI)
Controls (N ¼ 107) Symptomatic knee OA Analysis (Bold if signiﬁcant)
Low (N ¼ 113) High (N ¼ 96)
Heat temperatures (C)z
Forearm
WTh 36.1 (35.7, 36.6) 35.5 (35.1, 35.9) 35.3 (34.7, 35.8) F ¼ 2.81, n.s., hp2 ¼ .02
HPTh 42.7 (42.1, 43.3) 42.1 (41.5, 42.6) 41.4 (40.8, 72.1) F ¼ 3.19, P ¼ .04, hp2 ¼ .02
HPTo 46.7 (46.3, 47.1) 46.3 (45.9, 46.7) 45.8 (45.4, 46.3) F ¼ 3.21, P ¼ .04, hp2 ¼ .02
Knee
WTh 36.9 (36.4, 37.5) 37.1 (36.5, 37.5) 37.6 (37.1, 38.2) F ¼ 1.46, n.s., hp2 ¼ .01
HPTh 42.2 (41.6, 42.8) 42.1 (41.6, 42.7) 41.6 (40.9, 42.3) F ¼ .71, n.s., hp2 ¼ .01
HPTo 46.4 (45.9, 46.8) 46.2 (45.8, 46.6) 45.7 (45.2, 46.2) F ¼ 2.23, n.s., hp2 ¼ .01
VAS intensity ratingsz (Analysis completed with 92 control, 81 low symptomatic OA, and 76 high symptomatic OA participants)
Forearm
HPTh 19.6 (15.3, 23.9)* 17.9 (13.8. 22.1)y 27.6 (22.8, 32.5) F[ 4.62, P[ .011, hp2 [ .04
HPTo 52.5 (46.8, 58.2) 50.9 (45.4, 56.4)y 63.4 (56.9, 69.9) F[ 4.31, P[ .015, hp2 [ .04
Knee
HPTh 19.5 (14.7, 23.0)* 18.9 (14.7, 23.0)y 28.6 (23.6, 33.5) F[ 4.68, P[ .01, hp2 [ .04
HPTo 56.7 (50.7, 62.7) 53.9 (48.1, 59.9) 64.9 (58.0, 71.8) F ¼ 2.8, P ¼ .07, hp2 ¼ .02
Abbreviations: Visual Analog Scale, VAS.
* Group comparisons: Signiﬁcant group difference between the control and high symptomatic knee OA groups (P < .01, Bonferroni).
y Group comparisons: Signiﬁcant group difference compared between the low and high symptomatic knee OA groups (P < .01, Bonferroni).
z Covariates for adjusted analysis: Controlling for race (0¼NHW, 1¼ AA), study site (0¼UF, 1¼UAB), age,WPS (0¼No, 1¼ Yes), gender (0¼ Female, 1¼Male), and testing
sequence (0 ¼ Thermal First, 1 ¼ Pressure First) as a covariates. For VAS intensity ratings: Analysis completed with 92 control, 81 low symptomatic OA, and 76 high
symptomatic OA participants.
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(P’s > .05).
Mechanical pain
Table IV presents group differences in PPTh. After controlling for
covariates, group differences were observed at each testing site,
including at the index knee (P’s < .001) and non-knee sites
(P’s .002). Pair-wise comparisons revealed that participants in the
high symptomatic knee OA group required less pressure to produce
pain than the control group at both sites of the knee, quadriceps,
trapezius, and forearm (P’s < .01). However, participants in the low
and high symptomatic knee OA groups only differed at the kneeTable III
Adjusted means (95% conﬁdence interval) for pain rating for the ﬁrst trial and indexes of t
healthy controls and individuals with low and high symptomatic knee OA
Control (N ¼ 107) Symptomatic knee OA
Low (N ¼ 113)
Pain intensityz
Forearm
44 C 24.3 (19.4, 29.2)* 27.7 (23.2, 32.2)y
46 C 26.7 (24.4, 34.9)* 32.0 (27.3, 36.8)y
48 C 33.8 (28.3, 39.4)* 38.6 (33.5, 43.7)y
Knee
44 C 22.3 (17.8, 26.8) 21.7 (17.6, 25.9)
46 C 28.3 (23.3, 33.3)* 29.7 (25.2, 34.3)y
48 C 32.3 (26.8, 37.8)* 35.1 (30.1, 40.1)y
Temporal summationz
Forearm
44 C 5.8 (3.5, 8.2) 6.1 (3.9, 8.2)
46 C 6.5 (3.9, 8.9) 7.4 (5.2, 9.8)
48 C 11.6 (8.3, 14.9) 13.7 (10.6, 16.7)
Knee
44 C 3.5 (1.5, 5.5) 5.1 (3.2, 6.9)
46 C 7.1 (4.1, 10.1) 10.5 (7.7, 13.2)
48 C 10.3 (7.0, 13.5) 13.9 (10.9, 16.9)
* Group comparisons: Signiﬁcant group difference between the control and high sym
y Group comparisons: Signiﬁcant group difference compared between the low and hi
z Covariates for adjusted analysis: Controlling for race (0¼NHW, 1¼ AA), study site (0¼
sequence (0 ¼ Thermal First, 1 ¼ Pressure First) as a covariates.sites (P’s < .01). In Table V, differences among the control and
symptomatic OA groups in pain intensity ratings following a single
and a series of 10 punctate stimuli are reported for the hand and
knee. Controlling for covariates, the main effects of both trial (i.e.,
ﬁrst vs tenth trial) and group as well as their interaction were
signiﬁcant (P’s  .01) for the knee. For the hand, only the main
effect of group and its interaction with trial were signiﬁcant
(P’s  .001). Pair-wise comparisons revealed higher ratings at the
knee in the high symptomatic knee OA group compared to the
control and low symptomatic knee OA groups at the ﬁrst (P < .01)
and tenth (P < .01) trials. For the hand, pain ratings were higher at
the tenth trial (P< .01) in the high symptomatic group compared to
the other groups (P’s < .01). Additionally, signiﬁcant differences inemporal summation (highest ratinge rating at ﬁrst pulse) at the forearm and knee in
Analysis (bold if signiﬁcant)
High (N ¼ 96)
38.9 (33.5, 44.4) F[ 7.17, P[ .001, hp2 [ .05
43.7 (37.9, 49.5) F[ 6.10, P[ .003, hp2 [ .04
50.8 (44.6, 56.9) F[ 7.23, P[ .001, hp2 [ .05
30.6 (25.6, 35.6) F[ 3.8, P ¼ .02, hp2 [ .03
42.6 (36.9, 47.9) F[ 7.30, P[ .001, hp2 [ .05
48.6 (42.5, 54.6) F[ 7.53, P[ .001, hp2 [ .05
7.9 (1.3, 10.6) F ¼ .78, n.s., hp2 ¼ .01
8.9 (6.2, 11.7) F ¼ .73, n.s., hp2 ¼ .01
12.7 (8.9, 16.3) F ¼ .42, n.s., hp2 ¼ .00
5.6 (3.4, 7.9) F ¼ .38, n.s., hp2 ¼ .01
9.1 (5.7, 12.4) F ¼ 1.33, n.s., hp2 ¼ .01
12.7 (9.1, 16.3) F ¼ 1.34, n.s., hp2 ¼ .01
ptomatic knee OA groups (P < .01, Bonferroni).
gh symptomatic knee OA groups (P < .01, Bonferroni).
UF, 1¼UAB), age,WPS (0¼No, 1¼ Yes), gender (0¼ Female, 1¼Male), and testing
Table IV
Adjusted means (95% conﬁdence interval) for pressure pain thresholds at the knee and sites proximal and distal to the knee in healthy controls and individuals with low and
high symptomatic knee OA
Controls (N ¼ 107) Symptomatic knee OA Analysis (Bold if signiﬁcant)
Low (N ¼ 113) High (N ¼ 96)
Knee (kPa)x
Medial joint line (MJL) 368.6 (337.6, 399.6)* 334.9 (306.7, 363.2)y 253.1 (219.4, 286.9) F[ 11.05, P < .001, hp2 [ .07
Lateral joint line (LJL) 392.3 (360.4, 424.2)* 350.2 (321.1, 379.3)y 273.4 (238.6, 308.2) F[ 10.73, P < .001, hp2 [ .07
Leg (kPa)x
Quadriceps (Q) 545.2 (499.2, 591.1)*,z 450.8 (408.8, 492.7) 367.5 (317.3, 417.6) F[ 11.55, P < .001, hp2 [ .07
Upper body (kPa)x
Forearm (FA) 310.7 (278.0, 343.3)* 255.3 (225.3, 285.2) 218.6 (182.9, 254.3) F[ 6.34, P[ .002, hp2 [ .04
Trapezius (TP) 353.6 (203.5, 279.2)*,z 282.1 (250.5, 313.8) 241.3 (203.5, 279.2) F[ 8.57, P < .001, hp2 [ .06
Abbreviations: kilopascal, kPa.
* Group comparisons: Signiﬁcant group difference between the control and high symptomatic knee OA groups (P < .01, Bonferroni).
y Group comparisons: Signiﬁcant group difference compared between the low and high symptomatic knee OA groups (P < .01, Bonferroni).
z Group comparisons: Signiﬁcant group difference compared between the control and low symptomatic knee OA groups (P < .01, Bonferroni).
x Covariates for adjusted analysis: Controlling for race (0¼NHW, 1¼ AA), study site (0¼UF, 1¼UAB), age,WPS (0¼No, 1¼ Yes), gender (0¼ Female, 1¼Male), and testing
sequence (0 ¼ Heat First, 1 ¼ Pressure First), and study site (1 ¼Medial joint line First, 2 ¼ Lateral joint line First, 3 ¼ Quadriceps, 4 ¼ Forearm, 5 ¼ Trapezius) as a covariates.
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knee (P’s< .01), with participants in the high symptomatic knee OA
group exhibiting a greater increase in pain ratings from the ﬁrst
trial to the tenth trial compared to participants in the control and
low symptomatic knee OA groups (P’s < .01).
Cold pain
Table VI shows responses to the immersion of the right hand
into the cold-water bath at 16,12, and 8 C. Overall, the threshold to
report cold pain (CPTh) and the time to tolerance (CPTo) did not
differ among the three groups (P’s > .05). Evaluation of cold pain
intensity ratings across the three temperatures revealed signiﬁcant
group differences at 12 C and 8 C (P’s  .02). Further inspection
revealed that participants in the control group reported less cold
pain compared to the high symptomatic knee OA group at 8 C
(P < .01). For ratings of cold pain unpleasantness, ratings differed
among the groups only at 12 C, with participants in the control
(P’s < .01) group reporting lower unpleasantness compared to the
high symptomatic knee OA group.
CPM
As reported in the Table VII, evaluation of CPM was based on
change scores (i.e., pain ratings of the ﬁrst thermal pulse before andTable V
Adjusted means (95% conﬁdence interval) for pain ratings and indexes of temporal sum
stimulation with a punctate probe at the hand and knee (patella) in healthy controls and
Control (N ¼ 107) Symptomatic knee OA
Low (N ¼ 113) High (N ¼ 96)
Hand pain ratingsz
Hand
First trial 6.5 (3.9, 9.2)* 7.0 (4.6, 9.4)y 11.4 (8.5, 14.4)
Tenth trial 16.5 (12.2, 20.8)* 17.4 (13.5, 21.3)y 30.6 (25.8, 35.4)
Knee
First trial 11.4 (8.1, 14.6)* 9.8 (6.9, 12.7)y 16.9 (13.4, 20.5)
Tenth trial 24.3 (19.3, 29.3)* 25.9 (21.4, 30.4)y 43.6 (38.1, 49.2)
Temporal summationz
Hand 9.9 (6.9, 13.1)* 10.5 (7.6, 13.3)y 19.2 (15.7, 22.6)
Knee 12.9 (9.6, 16.3)* 16.2 (13.2, 19.2)y 26.7 (22.9, 30.3)
* Group comparisons: Signiﬁcant group difference between the control and high sym
y Group comparisons: Signiﬁcant group difference compared between the low and hi
z Covariates for adjusted analysis: Controlling for race (0¼NHW, 1¼ AA), study site (0¼
sequence (0 ¼ Thermal First, 1 ¼ Pressure First), and testing site (0 ¼ Hand First, 1 ¼ Paafter hand immersion). CPM is a commonly used model to evaluate
endogenous pain modulation, which commonly involves inhibition
of a heat pain stimulus during exposure to a second noxious con-
ditioning stimulus (i.e., cold-water). The main effect for group
(P < .01) was signiﬁcant, indicating that the high symptomatic OA
group reported greater heat pain compared to controls. However,
neither the main effect of time nor the interaction between group
and time reached signiﬁcance (P’s> .05). Overall, the procedure did
not detect signiﬁcant pain inhibition.
Discussion
In the current study, experimental pain sensitivity and modu-
lation were assessed in a sample of middle-aged and older adults
with and without symptomatic knee OA. OA participants were
divided into high and low symptom severity groups. Group differ-
ences emerged between the healthy controls, the low symptomatic
OA group, and the high symptomatic OA group for a number of
clinical and experimental outcomes. Results supported our hy-
pothesis that individuals with higher symptomatic OA would
exhibit greater sensitivity to experimental pain measures
compared to individuals without knee pain and those with lower
symptomatic OA. However, no differences between the groups in
pain inhibition were observed. Overall, among individuals pre-
senting with symptomatic knee OA, generalized sensitivity tomation (rating at tenth trial e rating at ﬁrst trial) following a single and repeated
individuals with low and high symptomatic knee OA
Analysis (Bold if signiﬁcant)
Group (G) Trial (T) T  G
F[ 8.23,
P < .001, hp2 [ .05
F ¼ 4.33, P ¼ .038,
hp
2 ¼ .02
F [ 8.6, P < .001,
hp
2 [ .06
F[ 10.85,
P[ .005, hp2 [ .07
F[ 8.07, P[ .005,
hp
2 [ .03
F [ 13.82, P < .001,
hp
2 [ .09
F[ 8.58, P < .001, hp2 [ .06
F[ 13.8, P < .001, hp2 [ .09
ptomatic knee OA groups (P < .01, Bonferroni).
gh symptomatic knee OA groups (P < .01, Bonferroni).
UF, 1¼UAB), age,WPS (0¼No, 1¼ Yes), gender (0¼ Female, 1¼Male), and testing
tella First) as a covariates.
Table VI
Adjusted means (95% conﬁdence interval) for threshold, tolerance, and pain ratings during cold immersions at 16, 12, and 8 C in healthy controls and individuals with low and
high symptomatic knee OA
Controls (N ¼ 107) Symptomatic knee OA group Analysis
Low (N ¼ 113) High (N ¼ 96)
Cold pain outcomes (seconds)
Threshold (CPTh)y
16 C 31.9 (28.2, 35.6) 33.1 (29.7, 36.5) 31.4 (27.3, 35.5) F ¼ .23, n.s., hp2 ¼ .00
12 C 18.5 (15.5, 21.4) 18.6 (15.9, 21.3) 18.7 (15.5, 31.9) F ¼ .01, n.s., hp2 ¼ .00
8 C 12.1 (9.9, 14.3) 12.8 (10.8, 14.8) 11.4 (8.9. 13.9) F ¼ .39, n.s., hp2 ¼ .00
Tolerance (CPTo)y
16 C 59.8 (58.8, 60.8) 58.8 (57.9, 59.7) 59.2 (58.2, 60.3) F ¼ 1.23, n.s., hp2 ¼ .01
12 C 53.6 (50.9, 56.3) 54.7 (52.2, 57.1) 51.7 (48.7, 54.6) F ¼ 1.13, n.s., hp2 ¼ .01
8 C 46.8 (43.1, 50.4) 48.6 (45.2, 51.9) 43.6 (39.5, 47.6) F ¼ 1.72 n.s., hp2 ¼ .01
Cold pain ratings (0e100)
Intensityy
16 C 29.5 (23.7, 35.3) 28.9 (23.7, 35.3) 38.5 (32.2, 44.8) F ¼ 2.80, n.s., hp2 ¼ .02
12 C 54.6 (48.2, 60.9) 55.9 (49.7, 61.3) 67.4 (60.4, 74.4) F[ 3.94, P[ .02, hp2 [ .03
8 C 65.9 (60.1, 71.8)* 70.3 (65.1, 75.5) 80.0 (73.7, 86.3) F[ 4.69, P[ .01, hp2 [ .03
Unpleasantnessy
16 C 34.8 (28.8, 40.9) 30.9 (25.4, 36.5) 10.8 (35.2, 48.4) F ¼ 3.00, P ¼ .05, hp2 ¼ .02
12 C 58.7 (52.4, 64.9)* 57.7 (52.1, 63.4) 70.7 (63.9, 77.6) F[ 4.40, P[ .013, hp2 [ .03
8 C 69.9 (64.1, 75.7) 72.4 (67.1, 77.6) 81.4 (75.1, 87.7) F ¼ 3.39, P ¼ .03, hp2 ¼ .02
* Group comparisons: Signiﬁcant group difference between the control and high symptomatic knee OA groups (P < .01 Bonferroni).
y Covariates for adjusted analysis: Controlling for race (0 ¼ NHW, 1 ¼ AA), study site (0 ¼ UF, 1 ¼ UAB), age, WPS (0 ¼ No, 1 ¼ Yes), and gender (0 ¼ Female, 1 ¼Male) as a
covariates.
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implications for mechanisms underlying OA and treatment.
Subgrouping of symptomatic OA
Using Quantitative sensory testing (QST) methods to phenotype
individuals with symptomatic OA offers another tool to examine
potential mechanisms contributing to their clinical symptoms.
Recent studies have highlighted differences in pain sensitivity
depending on the severity of clinical pain, which has been charac-
terized in OA10,11 and other conditions18,19. Based on clinical pain in
the past 24 h, two cohorts of participants with symptomatic OA
exhibited differences in experimental pain outcomes with the “se-
vere knee pain group” experiencingmore pain compared to the “mild
to moderate knee pain group”10. Finan et al.11 split a sample of per-
sons with knee OA into four groups based on clinical pain severity
(i.e., WOMAC) and radiographic OA severity and observed no group
differences in experimental pain measures at the affected knee.
However, these authors reported greater sensitivity outside the knee
in OA patients with high pain and low radiographic severity
compared to thosewith low pain and high radiographic severity. The
current studycorroborates and extendspriorﬁndings10,11 by showing
that greaterOA symptoms are associatedwith greater pain sensitivity
at both affected and unaffected sites including the forearm (pressure,
heat), shoulder (pressure), and hand (cold, mechanical punctate).Table VII
Adjustedmeans (95% conﬁdence interval) for changes to heat pain ratings before and follo
knee OA
Control (N ¼ 107) Symptomatic knee OA
Low (N ¼ 113) High (N ¼ 96)
Highest pain rating*
Pre-immersion 35.5 (30.2, 40.9) 40.8 (36.0, 45.6) 45.9 (40.1, 51.9)
Post-immersion 37.8 (32.7, 42.9) 43.6 (38.9, 48.2) 47.8 (42.3, 53.4)
Change score* 1.95 (1.5, 5.4) 2.3 (.7, 5.4) 1.4 (2.4, 5.2)
* Covariates for adjusted analysis: Controlling for race (0 ¼ NHW, 1 ¼ AA), study site
covariates.QST measures
The current study found differences in a majority of experi-
mental pain procedures as a function of symptomatic OA severity.
For HPTh and HPTo, no group differences emerged for any test site;
however, the lack of differences in HPTh and HPTo should be
interpreted in light of the pain ratings provided for each of these
measures. That is, while similar temperatures were required to
reach threshold and tolerance, these temperatures evoked greater
pain in the high symptom severity group. Moreover, pain ratings in
response to the series of heat pulses were greater in the high
symptom severity group at both sites tested. Taken together, these
ﬁndings suggest a generalized enhancement of heat pain sensitivity
in the high symptom severity group, consistent with central
sensitization.
Pressure pain has been shown to be effective in differentiating
controls and individuals with OA at the affected knee and remote
sites20 and demonstrates greater reliability within the OA popula-
tion compared to other QST methods21. In the current study, robust
differences in pressure pain were observed in which controls were
less sensitive at the knee and other sites compared to individuals
with highly symptomatic OA. Furthermore, the high vs low symp-
tomatic OA groups only differed at the knee. One of the unique
ﬁndings of the study is that pressure pain thresholds did not differ
between the low symptomatic and control groups at any site.wing hand immersion in healthy controls individualswith lowand high symptomatic
Analysis
Group (G) Time (T) T  G
F[ 6.06, P[ .003,
hp
2 [ .04
F ¼ .17, n.s., hp2 ¼ .00 F ¼ 0.41, n.s., hp2 ¼ .00
F ¼ .75, n.s., hp2 ¼ .01
(0 ¼ UF, 1 ¼ UAB), WPS (0 ¼ No, 1 ¼ Yes), and gender (0 ¼ Female, 1 ¼ Male) as a
C.D. King et al. / Osteoarthritis and Cartilage 21 (2013) 1243e1252 1249Similar ﬁndings have been reported previously. For example,
Arendt-Nielsen et al.10 assessed pressure pain thresholds at eight
sites around the symptomatic knee and one site at the forearm,
with results suggesting that the high severity OA group exhibited
lower pressure thresholds at all sites compared to controls. No
reference was made to the OA group with low pain, but inspection
of the means suggests responses similar to the present study.
Differences in cold pain sensitivity are not commonly assessed
in OA. Finan and colleagues11 observed higher cold pain ratings in
their high pain/low radiographic severity group compared to in-
dividuals with low pain/high radiographic severity. The authors
suggested that greater hypersensitivity in the unaffected site can be
used as a marker of central sensitization11. Similarly, in the current
study, ratings of pain intensity and unpleasantness at certain
temperatures were greater or trended toward greater in the high
symptomatic OA group after controlling for covariates, providing
further evidence of generalized pain hypersensitivity in this group.
A method commonly used to assess temporal summation in-
volves the repeated application of a thermal or mechanical stim-
ulus22. Temporal summation (i.e., greater pain during the course of
repeated stimulus presentation) is thought to reﬂect transient
central sensitization and is often greater in chronic pain cohorts.
Our temporal summation results varied depending on themodality.
For example, while general heat hyperalgesia was observed at the
forearm and the knee in the high symptomatic OA group, no dif-
ferences emerged in temporal summation of heat pain at either
site. However, greater temporal summation of mechanical pain at
the hand and knee was observed in the high symptomatic OA
group. While both represent measures of pain facilitation, different
mechanisms appear to underlie mechanical and thermal temporal
summation. Indeed, similar measures of thermal and mechanical
temporal summation were recently shown to load on different
factors, and patients with temporomandibular disorder differed
from controls only in their mechanical temporal summation23.
Thus, the mechanisms reﬂected by mechanical temporal summa-
tion may be more relevant for musculoskeletal pain.
Finally, lack of any modulatory effect following cold-water im-
mersion is atypical for studies related to CPM, which have reported
reduced endogenous pain inhibition in various chronic pain cohorts
compared to age- and/or gender-matched controls24. However, one
study reported no differences in CPM in OA patients11. In addition to
methodological factors, several explanations could account for
these results. First, the magnitude of CPM is affected by a number of
psychological25,26 and cognitive27 factors. Even though the current
study did not evaluate relationships among psychological func-
tioning and CPM, it is possible that these factors inﬂuenced CPM
responses. In addition, demographic factors such as older age28,
gender (i.e., lower CPM in females29), and race/ethnicity (i.e., lower
CPM in AfricaneAmericans30) are known to inﬂuence CPM. Thus, it
is possible that the lack of CPM was driven by our sample,
comprised predominantly of female and older participants.
Presumed mechanisms
The current study supports the possibility that the neurological
processes involved in the transmission and modulation of noci-
ceptive information differ as a function of OA symptom severity,
such that more severe OA pain is associated with augmented pro-
cessing (i.e., greater sensitivity to pressure pain and suprathreshold
heat and mechanical pain, cold pain). That these differences in
experimental pain sensitivity emerged across all stimulus modal-
ities and at both affected and unaffected body sites argues for a
central nervous system role. While historically considered a pe-
ripheral disease (i.e., nociceptive damage at the knee), increasing
evidence, including the current ﬁndings, implicate centralmechanisms in the clinical symptomatology of OA. Whether these
differences in central pain processing represent a consequence or a
cause of symptomatic knee OA cannot be ascertained by the current
study, but both possibilities are plausible. Regarding the former,
pathophysiological changes at the knee may include local changes
to inﬂammatory and anti-inﬂammatory markers31,32, which can
activate and sensitize peripheral nociceptors in joint tissues leading
to neuroplastic changes in the peripheral33 and central nervous
system (i.e., dorsal horn neurons, changes in receptive ﬁelds)33e35.
Consequently, central processing of painful information from the
knee will be augmented due to both peripheral and central
segmental sensitization8,36. This can be manifested by several
outcomes including increased sensitivity to painful (i.e., hyper-
algesia) stimuli applied to the affected site. However, once these
central changes transpire, nociceptive processing is enhanced in
the area of localized pain but also in secondary areas distant to
affected site, which is commonly observed as widespread
sensitivity.
Another possibility is that heightened pain sensitivity predates
the onset of symptomatic OA and represents a premorbid risk factor
for development of more severe symptoms as OA-related patho-
physiological changes occur. Indeed, previous studies have re-
ported that QST measures of pain sensitivity can predict future
development of clinical pain. For example, a global index of pain
sensitivity across multiple stimulus modalities predicted future
development of temporomandibular disorder37. Also, increased
sensitivity to cold and pressure pain shortly after a motor vehicle
accident predicted chronic whiplash symptoms one year following
the accident38. Finally, inadequate CPM measured before surgery
predicted development of chronic pain after surgery among pa-
tients undergoing thoracotomy39. Thus, it seems plausible that
heightened pain sensitivity and poorer pain inhibitory function
may confer increased risk for developing more severe OA-related
symptoms.
Treatment implications
Individual differences in severity of symptomatic OA may have
treatment implications. In the current study, participants were
categorized into low and high symptomatic OA groups based on
their clinical report of knee pain, stiffness, and disability on the
total WOMAC score, and these groups differed substantially in
both local and generalized pain sensitivity. Widespread central
sensitization may account for these individual differences in hy-
persensitivity to experimental stimuli10,36,40 and may contribute to
the severity of symptomatic knee OA9, which could have impli-
cations for tailoring treatment interventions to address central
mechanisms41. Thus, individuals with severe OA and WPS hyper-
sensitivity may require more centrally acting pharmacological
treatments. For example, duloxetine relieve OA pain due to its
central actions42,43. A recent study of neuropathic pain demon-
strated that patients with poorer pre-treatment pain inhibitory
function, assessed with CPM, showed better clinical response to
duloxetine44. However, clinical trials of duloxetine for OA have not
included experimental methods to determine the association of
central mechanisms with efﬁcacy. Finally, it is possible that the
heightened experimental sensitivity observed in individuals with
high symptomatic OA could be used to predict poor responses to
surgeries including total knee replacement (TKR) surgery. Based
on a recent prospective study in England, a strong predictor of
poor TKR outcomes was greater pre-operative pain45. Thus, using
experimental methods to identify at-risk patients could assist in
determining the use of more central acting medications that
would manage pain prior to surgery and in turn would lead to
better surgical outcomes.
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Several limitations of our study should be considered when
interpreting the ﬁndings. First, this study used median splits to
form group with differing OA symptom severity. Therefore, the
grouping, which is based on clinical pain severity, is data driven
rather than driven by a validated clinical cut-off. Second, the cur-
rent study did not explore other biopsychosocial factors contrib-
uting to OA symptom severity. For example, a greater number of
participants in the high symptomatic OA group were Africane
American, and ethnic and racial differences have been reported for
both clinical46,47 and laboratory-based assessments of pain (see
review48). However, to account for these effects, race was a covar-
iate in all analyses. In addition, psychosocial factors not reported in
this study may also differ as a function of OA symptom severity.
Based on the Biopsychosocial Model of Pain49, multiple factors can
explain individual differences in pain, and future studies should
include additional variables in order to explicate these ﬁndings.
Finally, while participants indicate the presence of pain over the
past 3 months, we did not assess the duration of pain experienced
in other areas of the body, which was used to determine WPS. It is
possible that experience of pain in sites outside the knee may also
indicate the presence of central sensitization.
Summary
In summary, the current study demonstrates that individuals
whose OA symptoms are more severe show local and widespread
increases in pain sensitivity compared to both controls and to in-
dividual with mildly symptomatic OA. This abnormal sensory
processing may reﬂect different underlying peripheral and/or
central mechanisms. Development of tools to differentiate sub-
groups of patients with symptomatic OA will enhance our under-
standing of this condition but also inform better preventative and
treatment options to individuals suffering with this condition.
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